All In Biotech

Drug Trial Radar · NCT04126200

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 208 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

208

Actual

Start

Oct 7, 2019

Primary completion

Apr 17, 2025

Study completion Mar 11, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.

Conditions

  • Multiple Myeloma

Interventions

  • Belantamab mafodotinDrug

    Belantamab mafodotin will be administered.

  • GSK3174998Drug

    GSK3174998 will be administered.

  • FeladilimabDrug

    feladilimab will be administered.

  • NirogacestatDrug

    Nirogacestat will be administered.

  • DostarlimabDrug

    Dostarlimab will be administered.

  • IsatuximabDrug

    Isatuximab will be administered.

  • LenalidomideDrug

    Lenalidomide will be administered.

  • DexamethasoneDrug

    Dexamethasone will be administered.

  • PomalidomideDrug

    Pomalidomide will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Randomized Across Sub-studiesTime frame: Day 1

Locations

38 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Grand Rapids, Michigan

  • GSK Investigational Site

    Madison, Wisconsin

  • GSK Investigational Site

    Porto Alegre, Brazil

  • GSK Investigational Site

    Salvador, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Halifax, Nova Scotia, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Lille, France

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Frankfurt, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Kiel, Germany

  • GSK Investigational Site

    Leipzig, Germany

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Mexico City, Mexico

  • GSK Investigational Site

    Leeuwarden, Netherlands

  • GSK Investigational Site

    Utrecht, Netherlands

  • GSK Investigational Site

    Oslo, Norway

  • GSK Investigational Site

    Gdansk, Poland

  • GSK Investigational Site

    Katowice, Poland

  • GSK Investigational Site

    Lodz, Poland

  • GSK Investigational Site

    Lublin, Poland

  • GSK Investigational Site

    Incheon, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Badalona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    PamplonaNavarra, Spain

  • GSK Investigational Site

    Pozuelo de AlarcOn Madr, Spain

  • GSK Investigational Site

    Falun, Sweden

  • GSK Investigational Site

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.